Vol.:(0123456789) 1 3
Infammopharmacology
https://doi.org/10.1007/s10787-019-00681-7
ORIGINAL ARTICLE
Chromium picolinate attenuates cognitive defcit in ICV‑STZ rat
paradigm of sporadic Alzheimer’s‑like dementia via targeting
neuroinfammatory and IRS‑1/PI3K/AKT/GSK‑3β pathway
Ansab Akhtar
1
· Jatinder Dhaliwal
1
· Priyanka Saroj
1
· Ankit Uniyal
1
· Mahendra Bishnoi
2
· Sangeeta Pilkhwal Sah
1
Received: 31 October 2019 / Accepted: 16 December 2019
© Springer Nature Switzerland AG 2020
Abstract
Alzheimer’s disease (AD) is prevalent in old age people and is one of the most common brain diseases. Brain insulin resist-
ance, neuroinfammation, oxidative stress, and mitochondrial and cholinergic dysfunction are key features of the disease.
In our study, streptozotocin (STZ) in a dose of 3 mg/kg was injected in male Wistar rats bilaterally through the intracer-
ebroventricular (ICV) route on stereotaxic apparatus. Chromium picolinate (CrPic) was tested at doses of 1 mg/kg, 2 mg/kg,
and 4 mg/kg, while rivastigmine (2 mg/kg) was used as reference standard drug. Cognitive dysfunction induced by STZ was
assessed by behavioral tests like Morris water maze and novel object recognition test. Treatment with CrPic revealed attenu-
ation of cognitive defcit. This was confrmed by behavioral tests, biochemical estimations of antioxidant enzymes, oxidative
stress, nitrosative stress, and cholinergic and mitochondrial activity. CrPic did not change AchE activity signifcantly. STZ-
induced neuroinfammation evident by increased TNF-α, IL-6, and CRP levels was also signifcantly decreased by CrPic.
Dysfunctional insulin signaling after ICV-STZ was demonstrated by reduced IRS-1, PI3K, AKT, BDNF gene expression,
and increased GSK-3β, NF-κB gene expression with the help of qRT-PCR. CrPic treatment produced an improvement in
insulin signaling revealed by increased gene expression of IRS-1, PI3-K, AKT, BDNF, and decreased gene expression of
GSK-3β and NF-κB. It was concluded that CrPic reversed AD pathology revealed by improved memory, reduced oxidative
stress, neuroinfammation, mitochondrial dysfunction, and upregulated insulin signaling.
Keywords ICV-STZ · Chromium picolinate · Oxidative stress · Neuroinfammation · Insulin resistance · Alzheimer’s
disease
Introduction
Alzheimer’s disease (AD) is one of the most common forms
of dementia afecting elderly people. People sufering from
AD show symptoms of cognitive impairment, memory def-
icit, and disturbances in behavioral activities (Onor et al.
2006). According to the 2017 report, around 44 million peo-
ple globally are sufering from AD with disease prevalence
likely to rise to 115 million by 2050 (Sargent and Brown
2017).
Despite more than 30 years of intense investigation, the
feld lacks consensus regarding the etiology and pathogen-
esis of sporadic AD, and therefore, we still do not know
the best strategies for treating and preventing this debilitat-
ing disease. Moreover, the prevalence of AD is increasing
rapidly in the absence of truly efective therapies. Epide-
miologic studies in elderly, experimental investigations in
humans and animal models consistently demonstrate that
Inflammopharmacology
* Sangeeta Pilkhwal Sah
spilkhwal@redifmail.com
Ansab Akhtar
ansabakhtar@gmail.com
Jatinder Dhaliwal
jatinderdhaliwal57@yahoo.com
Priyanka Saroj
priyanka1960@gmail.com
Ankit Uniyal
ankituniyal1994rsb@gmail.com
Mahendra Bishnoi
mbishnoi@gmail.com
1
Pharmacology Division, University Institute
of Pharmaceutical Sciences, Panjab University,
Chandigarh 160014, India
2
National Agri-Food Biotechnology Institute (NABI),
Sector-81, SAS Nagar, Mohali, Punjab 140306, India